Valuation: Beacon Pharmaceuticals PLC

Market Cap 25.48B 207M 182M 172M 156M 293M 19.86B 295M 2.06B 796M 10.13B 777M 760M 32.57B P/E 2024
68.2x
P/E 2025 25.8x
Enterprise Value 35.44B 288M 253M 239M 217M 408M 27.63B 410M 2.87B 1.11B 14.1B 1.08B 1.06B 45.3B EV / Sales 2024
4.25x
EV / Sales 2025 2.74x
Free-Float
36.94%
Yield 2024
1.3%
Yield 2025 1.98%
1 day-0.98%
1 week-1.95%
Current month-2.42%
1 month-3.55%
3 months-7.96%
6 months-1.85%
Current year-3.82%
1 week 100
Extreme 100
105.8
1 month 93.2
Extreme 93.2
107.4
Current year 93.2
Extreme 93.2
117.9
1 year 93.2
Extreme 93.2
124.4
3 years 92.4
Extreme 92.4
288.9
5 years 92.4
Extreme 92.4
393
10 years 16
Extreme 16
393
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 67 -
Director/Board Member 42 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.98%-1.95%-19.65%-58.94% 191M
+0.25%+1.97%+63.50%+118.18% 1,055B
+0.32%+0.86%+49.65%+73.25% 654B
+0.95%+0.95%+19.64%+75.37% 467B
-1.36%-2.58%+38.77%+42.33% 348B
+1.34%+4.53%+22.56%+29.55% 275B
-0.48%-0.54%+12.66%+13.50% 258B
+0.82%+6.47%+52.78%+54.56% 224B
+0.89%+1.29%+35.41%+102.20% 187B
-0.30%-2.98%-28.24%-61.28% 171B
Average +0.17%+0.60%+24.71%+38.87% 363.85B
Weighted average by Cap. +0.30%+1.32%+39.91%+70.08%

Financials

2024 2025
Net sales 10.7B 86.9M 76.43M 72.27M 65.55M 123M 8.34B 124M 865M 334M 4.26B 326M 319M 13.68B 12.54B 102M 89.58M 84.7M 76.83M 144M 9.78B 145M 1.01B 392M 4.99B 382M 374M 16.03B
Net income 521M 4.23M 3.72M 3.52M 3.19M 5.99M 406M 6.03M 42.13M 16.27M 207M 15.88M 15.54M 666M 947M 7.69M 6.76M 6.39M 5.8M 10.89M 738M 10.95M 76.53M 29.56M 376M 28.86M 28.23M 1.21B
Net Debt 10B 81.18M 71.39M 67.51M 61.23M 115M 7.79B 116M 808M 312M 3.98B 305M 298M 12.78B 9.96B 80.9M 71.16M 67.29M 61.03M 115M 7.77B 115M 806M 311M 3.96B 304M 297M 12.73B
Logo Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products, and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract and toll manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics, and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral, and biotech. Its products include Tagrix 80, Afanix 40, Ibrutix, Lenvanix 4, Palbonix, Crizonix, Sunitix, Wedica, Tafecta, Hernix, Obetix, Ribotix, among others.
Employees
4,771
Date Price Change Volume
28/09/26 BDT 100.60 -0.98% 48,081
27/09/26 BDT 101.60 -1.36% 31,650
24/09/26 BDT 103.00 -0.77% 107,014
23/09/26 BDT 103.80 +2.47% 81,563
22/09/26 BDT 101.30 -0.39% 59,224
  1. Stock Market
  2. Stocks
  3. BEACONPHAR Stock